<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02284217</url>
  </required_header>
  <id_info>
    <org_study_id>HS-009</org_study_id>
    <nct_id>NCT02284217</nct_id>
  </id_info>
  <brief_title>An Evaluation of Non-invasive ICP Monitoring in Patients Undergoing Invasive ICP Monitoring Via an External Ventricular Drainage (EVD) Device</brief_title>
  <official_title>A Prospective, Open-Label, Non-Randomized, Comparative Study Designed to Evaluate the Accuracy and Safety of HS-1000 Device, a Non-Invasive Intracranial Pressure (ICP) Monitor, in Patients Undergoing Invasive ICP Monitoring Procedure for Various Clinical Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HeadSense Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HeadSense Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Invasive intracranial pressure (ICP) monitoring is highly effective, but involves risks.
      HS-1000 measures ICP non-invasively by assessing the acoustic properties of the patient's
      head. HS-1000 device, a proprietary new non-invasive ICP monitor, is expected to safely and
      accurately monitor ICP with minimal discomfort to patients, and provide information about
      normal or elevated ICP levels to the physicians.

      The study objective is to compare the accuracy and safety profile of HS-1000, a non-invasive
      ICP monitor, to invasive ICP monitoring via an external ventricular drain (EVD)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HS-1000 device, a proprietary new non-invasive ICP monitor, is expected to safely and
      accurately monitor ICP with minimal discomfort to patients, and provide information about
      normal or elevated ICP levels to the physicians
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-hoc algorithm processing to compare ICP values (mmHg) of the HS-1000 device and invasive ICP monitor collected in each ICP monitoring cycle</measure>
    <time_frame>2 months after last patient \ last visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs through 48 hours from end of ICP monitoring with HS-1000 device</measure>
    <time_frame>48 hours from end of ICP monitoring</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of ear infections/irritations coded and graded using the adapted CTCAE dictionary provided to the site Principal Investigator (PI)</measure>
    <time_frame>48 hours from end of ICP monitoring</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Presence of High Intracranial Pressure</condition>
  <arm_group>
    <arm_group_label>Patients with invasive ICP monitor (EVD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hospitalized patients who have already been implanted with an invasive ICP monitor. Eligible patients will be enrolled into the study and HS-1000 headset portion of the device will be placed in their ears.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EVD</intervention_name>
    <description>ICP monitoring will be done in parallel for both HS-1000 and ICP monitoring via an EVD device (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals will last from 30 minutes to 6 hours, continuously depending on the patient's clinical condition. Each such interval may occur three times a day or more depending on the clinical condition of the patient.</description>
    <arm_group_label>Patients with invasive ICP monitor (EVD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult men and women subjects, aged 18 years old and over at screening visit

          -  Patients undergoing invasive ICP monitoring via an external ventricular drainage (EVD)
             device for clinical management

          -  Survival expectancy greater than one week

          -  Subject or legal authorized representative (per local regulation) is able and willing
             to comply with the requirements of the protocol

          -  Subject or legal authorized representative (per local regulation) is able to
             understand and sign written informed consent to participate in the study

        Exclusion Criteria:

          -  Subject with ear disease, ear trauma

          -  Subjects with a bony abnormality (skull defect)

          -  Subjects with severe head trauma in which the location and/or severity of the skull
             fracture(s), i.e. frank skull fracture or major joint dislocations may jeopardize
             HeadSense monitoring procedure

          -  Subjects with cerebral fluid (CSF) leakage from the ear (CSF Otorrhea)

          -  Known allergy or hypersensitivity to any of the test materials or contraindication to
             test materials

          -  For women of childbearing potential: pregnancy (positive pregnancy test) or
             breast-feeding

          -  Subjects currently enrolled in or less than 30 days post-participation in other
             investigational device or drug study(s), or receiving other investigational agent(s)

          -  Any condition that may jeopardize study participation (e.g., abnormal clinical or
             laboratory finding) or interpretation of study results, or may impede the ability to
             obtain informed consent (e.g., mental condition)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Olivi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nichol McBee, MPH, CCRP</last_name>
    <phone>(410) 614-6996</phone>
    <email>nmcbee@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan Jagid, MD</last_name>
      <phone>305-298-4594</phone>
      <email>JJagid@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Enrique Ginzburg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E Francois Aldrich, M.B.,Ch.B.</last_name>
      <phone>410-328-0937</phone>
      <email>FAldrich@Smail.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>E Francois Aldrich, M.B.,Ch.B.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael A. Williams, MD, FAAN</last_name>
      <phone>410-601-6490</phone>
      <email>michwill@lifebridgehealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael A. Williams, MD, FAAN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Olivi, MD</last_name>
      <phone>410-245-2206</phone>
      <email>aolivi@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Neeraj Naval, MD</last_name>
      <phone>(410) 409-8087</phone>
      <email>nnaval1@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Alessandro Olivi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro Health</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Steinmetz, MD</last_name>
      <phone>216-251-6990</phone>
      <email>msteinmetz@metrohealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael Steinmetz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erlangen University</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Rammensee, MD</last_name>
      <phone>09131-85-33001</phone>
      <email>rudolf.rammensee@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Rudolf Rammensee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oliver Ganslandt, MD</last_name>
      <phone>0711 278-33700</phone>
      <email>o.ganslandt@klinikum-stuttgart.de</email>
    </contact>
    <investigator>
      <last_name>Oliver Ganslandt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2014</study_first_posted>
  <last_update_submitted>April 27, 2016</last_update_submitted>
  <last_update_submitted_qc>April 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

